Your browser doesn't support javascript.
loading
A porcine model of osteosarcoma.
Saalfrank, A; Janssen, K-P; Ravon, M; Flisikowski, K; Eser, S; Steiger, K; Flisikowska, T; Müller-Fliedner, P; Schulze, É; Brönner, C; Gnann, A; Kappe, E; Böhm, B; Schade, B; Certa, U; Saur, D; Esposito, I; Kind, A; Schnieke, A.
Afiliação
  • Saalfrank A; Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany.
  • Janssen KP; Department of Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
  • Ravon M; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Flisikowski K; Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany.
  • Eser S; Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
  • Steiger K; Department of Pathology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
  • Flisikowska T; Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany.
  • Müller-Fliedner P; Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany.
  • Schulze É; Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany.
  • Brönner C; Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany.
  • Gnann A; Department of Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
  • Kappe E; Department of Pathology, Bavarian Animal Health Service, Poing, Germany.
  • Böhm B; Department of Pathology, Bavarian Animal Health Service, Poing, Germany.
  • Schade B; Department of Pathology, Bavarian Animal Health Service, Poing, Germany.
  • Certa U; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Saur D; Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.
  • Esposito I; Institute of Pathology, Heinrich-Heine-University of Düsseldorf, Düsseldorf, Germany.
  • Kind A; Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany.
  • Schnieke A; Chair of Livestock Biotechnology, Technische Universität München, Freising, Germany.
Oncogenesis ; 5: e210, 2016 Mar 14.
Article em En | MEDLINE | ID: mdl-26974205
ABSTRACT
We previously produced pigs with a latent oncogenic TP53 mutation. Humans with TP53 germline mutations are predisposed to a wide spectrum of early-onset cancers, predominantly breast, brain, adrenal gland cancer, soft tissue sarcomas and osteosarcomas. Loss of p53 function has been observed in >50% of human cancers. Here we demonstrate that porcine mesenchymal stem cells (MSCs) convert to a transformed phenotype after activation of latent oncogenic TP53(R167H) and KRAS(G12D), and overexpression of MYC promotes tumorigenesis. The process mimics key molecular aspects of human sarcomagenesis. Transformed porcine MSCs exhibit genomic instability, with complex karyotypes, and develop into sarcomas on transplantation into immune-deficient mice. In pigs, heterozygous knockout of TP53 was sufficient for spontaneous osteosarcoma development in older animals, whereas homozygous TP53 knockout resulted in multiple large osteosarcomas in 7-8-month-old animals. This is the first report that engineered mutation of an endogenous tumour-suppressor gene leads to invasive cancer in pigs. Unlike in Trp53 mutant mice, osteosarcoma developed in the long bones and skull, closely recapitulating the human disease. These animals thus promise a model for juvenile osteosarcoma, a relatively uncommon but devastating disease.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article